{"id":4103,"date":"2020-04-15T08:25:47","date_gmt":"2020-04-15T08:25:47","guid":{"rendered":"https:\/\/lynxee.consulting\/?p=4103"},"modified":"2023-01-26T09:12:53","modified_gmt":"2023-01-26T09:12:53","slug":"europe-efsa-recurring-issues-in-mammalian-toxicology-3","status":"publish","type":"post","link":"https:\/\/lynxee.consulting\/en\/europe-efsa-recurring-issues-in-mammalian-toxicology-3\/","title":{"rendered":"EUROPE \u2013 EFSA: Recurring issues in mammalian toxicology"},"content":{"rendered":"<p style=\"text-align: justify\">During the EFSA peer review of pesticide active substances under Regulation (EC) No. 1107\/2009, several aspects in the area of mammalian toxicology were identified by EFSA that needed discussion with experts from National Authorities in order to enhance the harmonisation of the risk assessment of active substances.<\/p>\n<p style=\"text-align: justify\">A new discussion was held at the Pesticide Peer Review Meeting 17 of October 2019. The following topics were addressed:<\/p>\n<ul>\n<li style=\"text-align: justify\">Experience gained and feedback on the assessment of endocrine disrupting (ED) properties with the EFSA\/ECHA guidance (<a href=\"https:\/\/lynxee.consulting\/en\/europe-publication-of-the-guidance-document-efsaecha-on-identifying-endocrine-disruptors\/\" target=\"_blank\" rel=\"noopener noreferrer\">2018<\/a>) \u2013 Points for a potential update of the guidance,<\/li>\n<li style=\"text-align: justify\">Possibility to apply to pesticides the new ECHA guidance on impurities in biocides (to be published),<\/li>\n<li style=\"text-align: justify\">Issues related to the assessment of isomers (<a href=\"https:\/\/lynxee.consulting\/en\/europe-efsa-guidance-risk-assessments-for-substances-impurities-and-transformation-products-that-may-have-stereoisomers\/\" target=\"_blank\" rel=\"noopener noreferrer\">EFSA guidance 2019<\/a>),<\/li>\n<li style=\"text-align: justify\">Issues related to the assessment of relevant metabolite in groundwater as regards genotoxicity,<\/li>\n<li style=\"text-align: justify\">Assessment of genotoxicity in chemical mixtures,<\/li>\n<li style=\"text-align: justify\">Use of <em>in silico<\/em> method for predicting genotoxicity endpoints,<\/li>\n<li style=\"text-align: justify\">Toxicological assessment of metabolites found as residues (<a href=\"https:\/\/lynxee.consulting\/en\/europe-document-guide-definition-residue-dietary-assessment\/\" target=\"_blank\" rel=\"noopener noreferrer\">EFSA guidance 2016<\/a>),<\/li>\n<li style=\"text-align: justify\">Possibility to use Benchmark Dose (BMD) when a NOAEL cannot be set in toxicological studies,<\/li>\n<li style=\"text-align: justify\">Top dose selection in (chronic) toxicology studies.<\/li>\n<\/ul>\n<p style=\"text-align: justify\">EFSA also presented an update on the following ongoing projects:<\/p>\n<ul>\n<li style=\"text-align: justify\">Use of <em>in vitro<\/em> interspecies comparative metabolism studies<i>,<\/i><\/li>\n<li style=\"text-align: justify\">Update of the OECD guidance notes on dermal absorption (<a href=\"https:\/\/www.oecd.org\/chemicalsafety\/testing\/48532204.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">ENV\/JM\/MONO(2011)36<\/a>),<\/li>\n<li style=\"text-align: justify\">Development of integrated approaches to testing and assessment (IATA) case studies on developmental neurotoxicity (DNT) risk assessment,<\/li>\n<li style=\"text-align: justify\">Development of adverse Outcome Pathway (AOP) for substances having ED properties.<\/li>\n<\/ul>\n<p style=\"text-align: justify\">Other issues (such as the use of historical control data in toxicology studies) were raised by experts and are reported for consideration in future discussions.<\/p>\n<p>&nbsp;<\/p>\n<p><b>To download:\u00a0<\/b><\/p>\n<p style=\"text-align: justify\"><a href=\"https:\/\/efsa.onlinelibrary.wiley.com\/doi\/epdf\/10.2903\/sp.efsa.2019.EN-1837\" target=\"_blank\" rel=\"noopener noreferrer\">EFSA Technical Report \u2013 Outcome of the pesticides peer review meeting on general recurring issues in mammalian toxicology<\/a> (26 March 2020)<\/p>\n<p>&nbsp;<\/p>\n<p><b>See also our previous articles:\u00a0<\/b><\/p>\n<p><a href=\"https:\/\/lynxee.consulting\/en\/europe-efsa-recurring-issues-in-mammalian-toxicology-2\/\" target=\"_blank\" rel=\"noopener noreferrer\">EUROPE \u2013 EFSA: Recurring issues in mammalian toxicology<\/a> (2018)<\/p>\n<p><a href=\"https:\/\/lynxee.consulting\/en\/europe-efsa-recurring-issues-in-mammalian-toxicology\/\" target=\"_blank\" rel=\"noopener noreferrer\">EUROPE \u2013 EFSA: Recurring issues in mammalian toxicology<\/a> (2016)<\/p>\n<p>&nbsp;<\/p>\n<p><b>Lynxee consulting<\/b>\u2019s team is at your disposal to answer your questions.<\/p>\n<p><b>Contact us!<\/b> <a href=\"https:\/\/lynxee.consulting\/en\/contact\/\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/lynxee.consulting\/en\/contact\/<\/a><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<h6>Photo credit: qimono\/pixabay<\/h6>\n","protected":false},"excerpt":{"rendered":"<p>During the EFSA peer review of pesticide active substances under Regulation (EC) No. 1107\/2009, several aspects in the area of mammalian toxicology were identified by EFSA<span class=\"excerpt-hellip\"> [\u2026]<\/span><\/p>\n","protected":false},"author":7,"featured_media":4095,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[36],"tags":[143,195],"class_list":["post-4103","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-regulation","tag-efsa","tag-human-health"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>EUROPE \u2013 EFSA: Recurring issues in mammalian toxicology - Lynxee consulting<\/title>\n<meta name=\"description\" content=\"During the EFSA peer review of pesticide active substances under Regulation (EC) No. 1107\/2009, several aspects in the area of mammalian toxicology were\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/lynxee.consulting\/en\/europe-efsa-recurring-issues-in-mammalian-toxicology-3\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EUROPE \u2013 EFSA: Recurring issues in mammalian toxicology - Lynxee consulting\" \/>\n<meta property=\"og:description\" content=\"During the EFSA peer review of pesticide active substances under Regulation (EC) No. 1107\/2009, several aspects in the area of mammalian toxicology were\" \/>\n<meta property=\"og:url\" content=\"https:\/\/lynxee.consulting\/en\/europe-efsa-recurring-issues-in-mammalian-toxicology-3\/\" \/>\n<meta property=\"og:site_name\" content=\"Lynxee consulting\" \/>\n<meta property=\"article:published_time\" content=\"2020-04-15T08:25:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-01-26T09:12:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/lynxee.consulting\/wp-content\/uploads\/2020\/04\/DNA-puzzle-2500333_1920.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1013\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Adrien Margerit\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Adrien Margerit\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-efsa-recurring-issues-in-mammalian-toxicology-3\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-efsa-recurring-issues-in-mammalian-toxicology-3\\\/\"},\"author\":{\"name\":\"Adrien Margerit\",\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/#\\\/schema\\\/person\\\/8bd656ad92ca721913ddf5433730d240\"},\"headline\":\"EUROPE \u2013 EFSA: Recurring issues in mammalian toxicology\",\"datePublished\":\"2020-04-15T08:25:47+00:00\",\"dateModified\":\"2023-01-26T09:12:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-efsa-recurring-issues-in-mammalian-toxicology-3\\\/\"},\"wordCount\":330,\"image\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-efsa-recurring-issues-in-mammalian-toxicology-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/lynxee.consulting\\\/wp-content\\\/uploads\\\/2020\\\/04\\\/DNA-puzzle-2500333_1920.jpg\",\"keywords\":[\"EFSA\",\"Human Health\"],\"articleSection\":[\"Regulation\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-efsa-recurring-issues-in-mammalian-toxicology-3\\\/\",\"url\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-efsa-recurring-issues-in-mammalian-toxicology-3\\\/\",\"name\":\"EUROPE \u2013 EFSA: Recurring issues in mammalian toxicology - Lynxee consulting\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-efsa-recurring-issues-in-mammalian-toxicology-3\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-efsa-recurring-issues-in-mammalian-toxicology-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/lynxee.consulting\\\/wp-content\\\/uploads\\\/2020\\\/04\\\/DNA-puzzle-2500333_1920.jpg\",\"datePublished\":\"2020-04-15T08:25:47+00:00\",\"dateModified\":\"2023-01-26T09:12:53+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/#\\\/schema\\\/person\\\/8bd656ad92ca721913ddf5433730d240\"},\"description\":\"During the EFSA peer review of pesticide active substances under Regulation (EC) No. 1107\\\/2009, several aspects in the area of mammalian toxicology were\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-efsa-recurring-issues-in-mammalian-toxicology-3\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-efsa-recurring-issues-in-mammalian-toxicology-3\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-efsa-recurring-issues-in-mammalian-toxicology-3\\\/#primaryimage\",\"url\":\"https:\\\/\\\/lynxee.consulting\\\/wp-content\\\/uploads\\\/2020\\\/04\\\/DNA-puzzle-2500333_1920.jpg\",\"contentUrl\":\"https:\\\/\\\/lynxee.consulting\\\/wp-content\\\/uploads\\\/2020\\\/04\\\/DNA-puzzle-2500333_1920.jpg\",\"width\":1920,\"height\":1013},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-efsa-recurring-issues-in-mammalian-toxicology-3\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EUROPE \u2013 EFSA: Recurring issues in mammalian toxicology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/#website\",\"url\":\"https:\\\/\\\/lynxee.consulting\\\/\",\"name\":\"Lynxee consulting\",\"description\":\"Innovative support for regulatory issues\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/lynxee.consulting\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/#\\\/schema\\\/person\\\/8bd656ad92ca721913ddf5433730d240\",\"name\":\"Adrien Margerit\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/AMA_WP-96x96.jpg\",\"url\":\"https:\\\/\\\/lynxee.consulting\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/AMA_WP-96x96.jpg\",\"contentUrl\":\"https:\\\/\\\/lynxee.consulting\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/AMA_WP-96x96.jpg\",\"caption\":\"Adrien Margerit\"},\"url\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/author\\\/adrien-margerit\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EUROPE \u2013 EFSA: Recurring issues in mammalian toxicology - Lynxee consulting","description":"During the EFSA peer review of pesticide active substances under Regulation (EC) No. 1107\/2009, several aspects in the area of mammalian toxicology were","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/lynxee.consulting\/en\/europe-efsa-recurring-issues-in-mammalian-toxicology-3\/","og_locale":"en_US","og_type":"article","og_title":"EUROPE \u2013 EFSA: Recurring issues in mammalian toxicology - Lynxee consulting","og_description":"During the EFSA peer review of pesticide active substances under Regulation (EC) No. 1107\/2009, several aspects in the area of mammalian toxicology were","og_url":"https:\/\/lynxee.consulting\/en\/europe-efsa-recurring-issues-in-mammalian-toxicology-3\/","og_site_name":"Lynxee consulting","article_published_time":"2020-04-15T08:25:47+00:00","article_modified_time":"2023-01-26T09:12:53+00:00","og_image":[{"width":1920,"height":1013,"url":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2020\/04\/DNA-puzzle-2500333_1920.jpg","type":"image\/jpeg"}],"author":"Adrien Margerit","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Adrien Margerit","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/lynxee.consulting\/en\/europe-efsa-recurring-issues-in-mammalian-toxicology-3\/#article","isPartOf":{"@id":"https:\/\/lynxee.consulting\/en\/europe-efsa-recurring-issues-in-mammalian-toxicology-3\/"},"author":{"name":"Adrien Margerit","@id":"https:\/\/lynxee.consulting\/#\/schema\/person\/8bd656ad92ca721913ddf5433730d240"},"headline":"EUROPE \u2013 EFSA: Recurring issues in mammalian toxicology","datePublished":"2020-04-15T08:25:47+00:00","dateModified":"2023-01-26T09:12:53+00:00","mainEntityOfPage":{"@id":"https:\/\/lynxee.consulting\/en\/europe-efsa-recurring-issues-in-mammalian-toxicology-3\/"},"wordCount":330,"image":{"@id":"https:\/\/lynxee.consulting\/en\/europe-efsa-recurring-issues-in-mammalian-toxicology-3\/#primaryimage"},"thumbnailUrl":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2020\/04\/DNA-puzzle-2500333_1920.jpg","keywords":["EFSA","Human Health"],"articleSection":["Regulation"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/lynxee.consulting\/en\/europe-efsa-recurring-issues-in-mammalian-toxicology-3\/","url":"https:\/\/lynxee.consulting\/en\/europe-efsa-recurring-issues-in-mammalian-toxicology-3\/","name":"EUROPE \u2013 EFSA: Recurring issues in mammalian toxicology - Lynxee consulting","isPartOf":{"@id":"https:\/\/lynxee.consulting\/#website"},"primaryImageOfPage":{"@id":"https:\/\/lynxee.consulting\/en\/europe-efsa-recurring-issues-in-mammalian-toxicology-3\/#primaryimage"},"image":{"@id":"https:\/\/lynxee.consulting\/en\/europe-efsa-recurring-issues-in-mammalian-toxicology-3\/#primaryimage"},"thumbnailUrl":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2020\/04\/DNA-puzzle-2500333_1920.jpg","datePublished":"2020-04-15T08:25:47+00:00","dateModified":"2023-01-26T09:12:53+00:00","author":{"@id":"https:\/\/lynxee.consulting\/#\/schema\/person\/8bd656ad92ca721913ddf5433730d240"},"description":"During the EFSA peer review of pesticide active substances under Regulation (EC) No. 1107\/2009, several aspects in the area of mammalian toxicology were","breadcrumb":{"@id":"https:\/\/lynxee.consulting\/en\/europe-efsa-recurring-issues-in-mammalian-toxicology-3\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/lynxee.consulting\/en\/europe-efsa-recurring-issues-in-mammalian-toxicology-3\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/lynxee.consulting\/en\/europe-efsa-recurring-issues-in-mammalian-toxicology-3\/#primaryimage","url":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2020\/04\/DNA-puzzle-2500333_1920.jpg","contentUrl":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2020\/04\/DNA-puzzle-2500333_1920.jpg","width":1920,"height":1013},{"@type":"BreadcrumbList","@id":"https:\/\/lynxee.consulting\/en\/europe-efsa-recurring-issues-in-mammalian-toxicology-3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/lynxee.consulting\/en\/"},{"@type":"ListItem","position":2,"name":"EUROPE \u2013 EFSA: Recurring issues in mammalian toxicology"}]},{"@type":"WebSite","@id":"https:\/\/lynxee.consulting\/#website","url":"https:\/\/lynxee.consulting\/","name":"Lynxee consulting","description":"Innovative support for regulatory issues","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/lynxee.consulting\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/lynxee.consulting\/#\/schema\/person\/8bd656ad92ca721913ddf5433730d240","name":"Adrien Margerit","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2023\/10\/AMA_WP-96x96.jpg","url":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2023\/10\/AMA_WP-96x96.jpg","contentUrl":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2023\/10\/AMA_WP-96x96.jpg","caption":"Adrien Margerit"},"url":"https:\/\/lynxee.consulting\/en\/author\/adrien-margerit\/"}]}},"_links":{"self":[{"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/posts\/4103","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/comments?post=4103"}],"version-history":[{"count":6,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/posts\/4103\/revisions"}],"predecessor-version":[{"id":6137,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/posts\/4103\/revisions\/6137"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/media\/4095"}],"wp:attachment":[{"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/media?parent=4103"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/categories?post=4103"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/tags?post=4103"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}